Mar 06th 2013 - Edison Investment Research today published a report on QRxPharma entitled "NDA Resubmitted". In summary, the report says:
QRxPharma has resubmitted its NDA for Q8003/MoxDuo IR for moderate-to-severe acute pain, putting it on track to undergo an Advisory Committee review in late Q2 and potentially obtain approval in Q3 this year. The filing contains additional data requested by the FDA following the complete response letter (CRL) received last year. Separate filings are expected in Canada, the EU and Australia in H1 of CY13.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »